The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549 **FORM D** 

## OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity			
CIK (Filer ID Number)	Previous	None	Entity Type
0001401914	Names		
Name of Issuer	Cerulean Phar		X Corporation
Dare Bioscience, Inc.	Tempo Pharm	aceuticais inc	Limited Partnership
Jurisdiction of Incorporation/Organic	ganization		Limited Liability Company
DELAWARE	gariizatiori		General Partnership
Year of Incorporation/Organization	tion		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Spe	acify Vaar)		
Yet to Be Formed	cony reary		
Tet to be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Dare Bioscience, Inc.			
Street Address 1		Street Address 2	
3655 NOBEL DRIVE		SUITE 260	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO	CALIFORNIA	92122	858-926-7655
3. Related Persons			
Last Name	First Name		Middle Name
Johnson	Sabrina		Martucci
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92122
Relationship: X Executive Off	icer X Director Promoter		
Clarification of Response (if New	cessary):		
Last Name	First Name		Middle Name
Walters-Hoffert	Lisa		
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92122
Relationship: X Executive Off	icer Director Promoter		
Clarification of Response (if Ne	cessary):		
Last Name	First Name		Middle Name
Rastetter	William		H.
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92122
Relationship: Executive Offi	cer X Director Promoter		

Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Blanchard	Cheryl	R.	
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92122	
Relationship: Executive Officer			
. Ш			
Clarification of Response (if Necess	sary): 		
Last Name	First Name	Middle Name	
Grossman	Jessica	D.	
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Kelley Street Address 1	Susan	L.	
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260	710/0 1 10 1	
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Matz	Gregory	W.	
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Ononye-Onyia	Sophia	N.	
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Steele	Robin	J.	
Street Address 1	Street Address 2		
3655 Nobel Drive	Suite 260		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92122	
		<del></del>	
Clarification of Response (if Necess	sary):		
4. Industry Group			

	Health Care	Retailing			
Banking & Financial Services	X Biotechnology	Restaurants			
Commercial Banking	Health Insurance	Technology			
Insurance	Hospitals & Physicians	Computers			
Investing					
Investment Banking	Pharmaceuticals	Telecommunications			
Pooled Investment Fund	Other Health Care	Other Technology			
	Manufacturing	Travel			
an investment company under the Investment Company	Real Estate	Airlines & Airports			
Act of 1940?	Commercial	Lodging & Conventions			
∐Yes ∐No	Construction	Tourism & Travel Services			
Other Banking & Financial Services	REITS & Finance	Other Travel			
Business Services	Residential	Other			
Energy  Coal Mining	Other Real Estate				
Electric Utilities					
Energy Conservation					
Environmental Services					
Oil & Gas					
Other Energy					
5. Issuer Size					
Revenue Range OR	Aggregate Net Asset Val	lue Range			
No Revenues	No Aggregate Net As	set Value			
\$1 - \$1,000,000	\$1 - \$5,000,000				
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	0,000			
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,00	00,000			
\$25,000,001 -	\$50,000,001 - \$100,0	000 000			
\$100,000,000					
Over \$100,000,000	Over \$100,000,000				
X Decline to Disclose	Decline to Disclose				
Not Applicable	Not Applicable				
6. Federal Exemption(s) and Exclusion(s) Cla	med (select all that apply)				
Investment Company Act Section 3(c)					
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)			
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)			
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)			
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)			
X Rule 506(b)					
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)			
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)			
	Section 3(c)(7)				
7. Tong of Filling					
7. Type of Filing					
X New Notice Date of First Sale 2023-12-21	First Sale Yet to Occur				
Amendment					
8. Duration of Offering					
Does the Issuer intend this offering to last more than one year? X Yes No					
9. Type(s) of Securities Offered (select all that apply)					

	Equity	Į	Pooled Investment Fund Interests		
	Debt	[	Tenant-in-Common Securities		
X	Option, Warrant or Other Right to Acquire Another Security	ĺ	Mineral Property Securities		
X	Security to be Acquired Upon Exercise of Option, Warrant or Othe Right to Acquire Security	er [	Other (describe)		
10.	Business Combination Transaction				
	this offering being made in connection with a business combination erger, acquisition or exchange offer?	n tra	nnsaction, such as a Yes X No		
Cla	rification of Response (if Necessary):				
11.	Minimum Investment				
Mi	nimum investment accepted from any outside investor \$0 USD				
12.	Sales Compensation				
Re	ecipient	cipie	ent CRD Number X None		
(A	ssociated) Broker or Dealer $\overline{X}$ None (As	ssoc	siated) Broker or Dealer CRD Number 🔀 None		
			Address 2		
Cit	´	te/P	Province/Country	ZIP/Postal Code	
	ate(s) of Solicitation (select all that apply) neck "All States" or check individual States	For	eign/non-US		
13.	Offering and Sales Amounts				
To	tal Offering Amount \$4,160,400 USD or Indefinite				
	tal Amount Sold \$1,733,500 USD				
To	tal Remaining to be Sold \$2,426,900 USD or Indefinite				
OI-					
	rification of Response (if Necessary):				
	al offering amount includes the \$0.3467 per underlying share of common are, assuming certain conditions are met, and the aggregate exercise price			to be issued in the	
14.	Investors				
Г	Select if securities in the offering have been or may be sold to pe				
	I enter the number of such non-accredited investors who already h		_	1	
	Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:				
15.	Sales Commissions & Finder's Fees Expenses				
	·	20.01	venences if any. If the amount of an expanditure is not	known provido	
	ovide separately the amounts of sales commissions and finders fee estimate and check the box next to the amount.	:S E	xpenses, if any. If the amount of an expenditure is not	known, provide	
	Sales Commissions \$0 USD Estimate				
	Finders' Fees \$0 USD Estimate				
Cla	rification of Response (if Necessary):				
16.	Use of Proceeds				
be	ovide the amount of the gross proceeds of the offering that has been named as executive officers, directors or promoters in response to box next to the amount.				
	\$0 USD Estimate				
Cla	urification of Response (if Necessary):				
Sig	nature and Submission				
	ease verify the information you have entered and review the Te file this notice.	erms	s of Submission below before signing and clicking	SUBMIT below	
Ter	rms of Submission				

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Dare Bioscience, Inc.	/s/ Lisa Walters-Hoffert	Lisa Walters-Hoffert	Chief Financial Officer	2023-12-26

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<sup>\*</sup> This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.